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Abstract
Background: HIV-1 integrase (IN) is a key viral enzymatic molecule required for the integration of the
viral cDNA into the genome. Additionally, HIV-1 IN has been shown to play important roles in several
other steps during the viral life cycle, including reverse transcription, nuclear import and chromatin
targeting. Interestingly, previous studies have demonstrated that the expression of HIV-1 IN induces the
lethal phenotype in some strains of Saccharomyces cerevisiae. In this study, we performed mutagenic
analyses of the C-terminal region of the catalytic core domain of HIV-1 IN in order to delineate the critical
amino acid(s) and/or motif(s) required for the induction of the lethal phenotype in the yeast strain HP16,
and to further elucidate the molecular mechanism which causes this phenotype.
Results: Our study identified three HIV-1 IN mutants, V165A, A179P and KR186,7AA, located in the C-
terminal region of the catalytic core domain of IN that do not induce the lethal phenotype in yeast.
Chromatin binding assays in yeast and mammalian cells demonstrated that these IN mutants were impaired
for the ability to bind chromatin. Additionally, we determined that while these IN mutants failed to interact
with LEDGF/p75, they retained the ability to bind Integrase interactor 1. Furthermore, we observed that
VSV-G-pseudotyped HIV-1 containing these IN mutants was unable to replicate in the C8166 T cell line
and this defect was partially rescued by complementation with the catalytically inactive D64E IN mutant.
Conclusion: Overall, this study demonstrates that three mutations located in the C-terminal region of
the catalytic core domain of HIV-1 IN inhibit the IN-induced lethal phenotype in yeast by inhibiting the
binding of IN to the host chromatin. These results demonstrate that the C-terminal region of the catalytic
core domain of HIV-1 IN is important for binding to host chromatin and is crucial for both viral replication
and the promotion of the IN-induced lethal phenotype in yeast.
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Background
HIV-1 belongs to the Lentiviridae genus of retroviruses and
its replication depends on the integration of the reverse-
transcribed viral genome into the host chromosome. This
viral integration step is not only essential for HIV-1 pro-
ductive replication, but also critical for the re-activation of
HIV-1 latent infection. It has been shown that the uninte-
grated HIV-1 in some resting CD4+ T lymphocytes pro-
vides an inducible and functional reservoir and its
activation requires viral DNA integration [1,2]. The HIV-1
integrase (IN) is the key viral enzyme required for this
integration step. IN is a 32 kDa protein with three distinct
structural domains, the N-terminal zinc-binding domain,
the central catalytic core domain and the C-terminal
domain. The catalytic core domain contains three highly
conserved residues Asp64, Asp116 and Glu152 (the DDE
motif) that are essential for the catalytic activity of IN.
Integration proceeds in three steps: (1) 3' processing,
when IN cleaves dinucleotides from the 3' end of the viral
DNA molecule; (2) strand transfer, when IN joins the 3'
ends of the viral DNA to the host DNA; and (3) gap repair,
when the 5' ends of the viral DNA are joined to the host
DNA by the host DNA repair enzymes. Integration of the
viral DNA into the host genome is not random but rather
favors active transcription units. This is driven by cellular
proteins which tether the lentiviral preintegration com-
plexes to specific sites on the host chromosomes. Indeed,
several cellular proteins, including LEDGF/p75, integrase
interactor-1 (Ini1) and barrier-to-autointegration (BAF),
have been identified that interact with IN and contribute
to its activities during integration and/or other early steps
of the HIV-1 life cycle (reviewed in [3]).
The importance of LEDGF/p75 in the activity of IN
throughout the viral life cycle has been extensively stud-
ied. LEDGF/p75 belongs to the hepatoma-derived growth
factor (HDGF) family and was initially described as a tran-
scriptional co-activator that regulates the cell stress
response. Recent studies have shown that LEDGF/p75
directly interacts with HIV-1 IN [4] and this interaction is
required for targeting of HIV-1 DNA to the chromosome
[5-7]. The interaction of IN with LEDGF/p75 has been
mapped to the residues W131/W132 and the region of
I161-E170 in the catalytic core domain of IN [8-10]. In
addition, the association of LEDGF/p75 with IN has also
been shown to protect IN from proteasomal degradation
[11]. Depletion of LEDGF/p75 by either RNAi or genetic
knockout in mammalian cells have been shown to abol-
ish the nuclear/chromosomal localization of IN, as well as
viral replication [6,7,12]. Another cellular co-factor Ini1
was originally discovered in a yeast two-hybrid system
screening for cellular proteins interacting with IN [13].
Ini1 is a subunit of the SWI/SNF chromatin-remodeling
complex [14] and it has been shown to increase the effi-
ciency of integration in an in vitro assay [13]. Further stud-
ies have also found that Ini1 is capable of being
incorporated into the HIV-1 virion and can modulate
reverse transcription and Tat-mediated transcription [15-
17]. All of these observations suggest that HIV-1 IN
hijacks different cellular proteins to aid in different steps
during the early viral replication.
Besides integration, IN also plays a role in other steps dur-
ing early HIV-1 replication, including reverse transcrip-
tion, nuclear import, and chromosomal targeting [18-25].
However, since mutations in IN have pleiotropic effects, it
is difficult to specifically study the effects of individual
mutations on one particular function of IN during viral
replication. Therefore, other functional assays have been
developed in order to elucidate the mechanisms underly-
ing the biological activities of IN in eukaryotic cells. Sev-
eral previous studies have reported a yeast eukaryotic
system in which the expression of IN alone in some Sac-
charomyces cerevisiae (S. cerevisiae) strains, such as the
W303-1A rad52 mutant strain and the AB2 diploid strain,
resulted in a lethal phenotype [26,27]. Additional studies
revealed that the IN-induced lethal phenotype may be
related to the catalytic activity of IN as an IN catalytic
mutant (D116A) was unable to induce the lethal pheno-
type in yeast [27,28]. Moreover, it has also been shown
that IN failed to induce the lethal phenotype in yeast cells
when the SNF5 gene, which encodes a component of the
SWI/SNF chromatin remodeling complex, was disrupted
[29]. As Ini1 is the human homolog of SNF5, this suggests
that IN-Ini1 interaction is required in order to induce the
lethal phenotype in yeast. Additionally, these studies
demonstrate that this "yeast lethal assay" is an ideal
model system to investigate the activities of IN during the
integration process. Interestingly, a recent study has
reported that a specific point mutation targeting E152 in
IN, one of the three critical residues (D64, D116 and
E152) essential for the catalytic activity of IN, did not dis-
rupt the ability of IN to induce the lethal phenotype in
yeast cells [30]. Thus, the mechanism for the IN-induced
lethal phenotype in yeast still remains to be defined and
it is likely that other functions of IN are important in
inducing the lethal phenotype in S. cerevisiae.
In order to further characterize the mechanism(s) under-
lying the IN-induced lethal phenotype in yeast, as well as
to determine the importance of the C-terminal region of
the catalytic core domain of HIV-1 IN in the viral life cycle,
we have generated a series of IN mutations. These mutants
allowed us to delineate the region(s) and/or amino acids
important in inducing the lethal phenotype in the S. cere-
visiae strain HP16. Using these mutants, we have identi-
fied several residues (V165, A179, KR186,7) located in the
C-terminal region of the catalytic core domain of HIV-1
IN that are required for the IN-induced lethal phenotype.
Additionally, we demonstrate that in both yeast andRetrovirology 2008, 5:102 http://www.retrovirology.com/content/5/1/102
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mammalian cells these IN mutants were impaired in their
ability to associate with cellular chromosomes. Interest-
ingly, our data also show that these IN mutants were una-
ble to bind to LEDGF/p75 in 293T cells and the
introduction of these mutants into HIV-1 rendered the
virus non-infectious. Furthermore, our data also indicated
that this replication defect was partially complemented by
the IN class I catalytic mutant D64E. These results high-
light the importance of the C-terminal region of the cata-
lytic core domain of HIV-1 IN in its association with the
chromatin of the host cell, viral replication and the IN-
induced lethal phenotype in yeast.
Results
Effects of IN mutations on the lethal activity in HP16 yeast 
cells
Caumont et al first demonstrated that HIV-1 IN induced a
lethal phenotype in some yeast strains, including the JSC
302, W839-5C and AB2 strains, but not in the W303-1
strain (Rad52+) [26]. In this study, we tested whether
HIV-1 IN could induce the lethal phenotype in the S. cer-
evisiae strain HP16 (MATa ura3-52; his3Δ1; leu2; trp1Δ63;
prb1-1122; pep4-3 prc1-407). A yeast expression plasmid
encoding the HIV-1 IN cDNA under the control of the
galactose-inducible GAL1 promoter (p424Gal1-IN) was
constructed and transformed into HP16 yeast cells which
were cultured in inducible media (Trp-, 2% galactose
(Gal)). The empty vector was used as control. Following
the confirmation of IN expression in p424Gal1-IN-trans-
formed yeast cells (Fig. 1D, upper panel and data not
shown), the lethality assay was conducted in liquid media
(Fig. 1B) and agar plates by the "drop test" (Fig. 1A).
When cultured in the induction media (Trp-, 2% Gal),
yeast cells transformed with p424Gal1-IN exhibited a sig-
nificant growth inhibition (Fig. 1A, right panel; Fig 1B,
lower panel). This indicates that the expression of HIV-1
IN in the HP16 yeast strain is able to induce the lethal
phenotype.
Previous studies have indicated that the catalytic activity
of IN may be required for IN-induced lethality in yeast
since introduction of an IN catalytic mutant (D116A) was
not lethal in the yeast strain AB2 [27,28]. However,
another study by Calmels et al reported that a specific IN
single point mutation targeting amino acid E152, another
crucial residue important for IN catalytic activity, did not
disrupt IN's lethal activity in yeast cells [30]. To test
whether the IN catalytic mutants could induce the lethal
phenotype in HP16 yeast strain, we first introduced the
class I IN mutants D64E, D116A and the double mutant
(D64E/D116A) into yeast strain HP16 and determined
their effect on yeast growth. Intriguingly, the expression of
each of these three IN mutants in yeast cells still induced
a lethal phenotype similar to the phenotype seen follow-
ing the wild type IN expression (Fig. 1A and 1B). Moreo-
ver, like the wild type IN, the D64E/D116A mutant
induced the lethal phenotype in a dose-dependent man-
ner in the presence of galactose (Fig. 1C and 1D). This
demonstrates that the catalytic function of IN is not
required for the induction of the lethal phenotype in the
HP16 yeast strain.
In order to further identify the critical amino acid(s) or
motif(s) in IN important in the induction of the lethal
phenotype, various IN mutants, including F1A, K136A,
K159P, V165A, A179P, KR186,7AA, KK215,9AA and
RK263,4AA, were introduced into HP16 yeast cells. Most
of these mutants have been previously shown to disrupt
HIV-1 replication at different steps, including proviral
DNA integration [19,31-35]. As determined by an anti-IN
IP and western blot (WB), transformation of plasmids
encoding these IN mutants resulted in comparable IN
expression after transformed yeast cells were cultured in
the inducible medium for 6 hours (Fig. 2A lanes 2–10). In
such short period of induction, the expression of IN did
not have significant effect on yeast growth nor the cell via-
bility (data not shown). Endogenous yeast β-actin was
used as internal control. The effect of each mutant IN on
yeast growth was measured in both liquid media and agar
plates, as described above. Interestingly, our steady state
analyses revealed that in the inducible media, yeast cells
transformed with different IN mutants showed varying
growth (Fig. 2B and 2C). In particular, cells transformed
with the IN mutants V165A, A179P or KR186,7AA had
growth rate similar to the yeast cells transformed with
empty vector, indicating that these three mutations, all
located in the C-terminal region of the IN catalytic core
domain, are unable to induce the lethal phenotype in the
HP16 yeast strain. As such, we designated them as lethal
phenotype-defective IN mutants. Therefore, these data
indicate that the IN-induced lethal phenotype in HP16
yeast cells is not related to the catalytic activity of IN. This
suggests that other functions of IN, which were affected by
each of these three mutations, may play an important role
for IN lethality in HP16 yeast strain.
Lethal phenotype-defective IN mutants are unable to 
efficiently associate with host chromatin
While the IN mutants identified in this study do not
induce the lethal phenotype in HP16 cells, the mecha-
nisms underlying this loss of lethality remained
unknown. A recent study has demonstrated that the
expression of IN in yeast could catalyze the integration of
DNA containing the LTRs of HIV into the yeast genome
with the same specificity in yeast and human cells [36].
This suggests that IN may utilize similar cellular machin-
ery, including proteins important for chromatin tethering,
for the integration process in yeast and mammalian cells.
Therefore, we tested whether the lethal phenotype-defec-
tive mutants might affect the association of IN with chro-Retrovirology 2008, 5:102 http://www.retrovirology.com/content/5/1/102
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matin by a chromatin binding assay, as previously
described [37]. Yeast cells expressing either the wild type
or mutant IN were spheroplasted and lysed in a buffer
containing 1% Triton X-100 for 5 min. The whole cell
extracts were then incubated with 50 mM or 200 mM
NaCl for 20 min and the chromatin-bound and non-chro-
matin-bound fractions were separated, as described in the
Materials and Methods. An anti-IN WB of chromatin-
bound and non-chromatin-bound fractions showed that
the wild type IN was exclusively detected in the chroma-
tin-bound fraction, whereas the chromatin binding of the
three lethal phenotype-defective IN mutants was impaired
to differing degrees. Approximately 10% of the KR186,
7AA IN bound chromatin and the association of the
V165A and A179P IN with chromatin was also reduced to
approximately 70% of the wild type level (Fig. 3A). As a
control, the localization of the yeast homocitrate synthase
isoenzymes Lys20/21p [38] was also evaluated and, as
HIV-1 IN-induced lethal phenotype in HP16 yeast strain is independent of its catalytic activity Figure 1
 HIV-1 IN-induced lethal phenotype in HP16 yeast strain is independent of its catalytic activity.  A. The effect of 
IN expression on yeast growth by the “drop test”. Equal amounts of different p424Gal1-IN transformed yeast cells were seri-
ally diluted and spotted onto either non-inducible agar plates (left panel) or inducible agar plates (right panel). After 3 to 5 days, 
yeast growth was recorded photographically. B. The effect of HIV-1 IN on yeast growth in liquid culture. Transformed yeast 
cells were grown in non-inducible media (upper panel) or in inducible media (lower panel) at 30°C for 24 h. Yeast growth was 
monitored by the measurement of yeast culture density by spectrophotometric analysis at a wavelength of 600 nm (A600). C. 
IN-mediated yeast growth arrest in a galactose dose-dependent manner. Equal amounts of p424-Gal-IN- and p424-Gal-IN-
DD64/116E/A-transformed yeast cells were cultured in different concentrations of galactose for 2 days and the yeast growth 
was then monitored by spectrophotometric assay. D. IN expression levels were detected in yeast cells in inducible media con-
taining different concentrations of galactose for 6 hrs. Then, cells were lysed and subjected to IP with anti-HIV serum followed 
by WB with anti-IN antibody.  Retrovirology 2008, 5:102 http://www.retrovirology.com/content/5/1/102
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expected, Lys20/21p were exclusively associated with
non-chromatin fraction (Fig. 3A, right panel).
In order to determine whether these IN mutations also
affected their chromatin binding in mammalian cells, we
tested the binding of the IN mutants to chromatin in 293T
cells using a chromatin isolation protocol as described
previously [39]. As a control, the YFP protein in trans-
fected 293T cells and the endogenous nuclear pore com-
plex-associated protein Nup62 [40] were analyzed for
their chromatin association.  Results showed that up to
20–25% of the wild type IN and mutants D64E and
K136A were detected in the chromatin-bound P1 fraction
(Fig. 3B, left panel, lanes 2 to 4). Similar to what was
observed in yeast cells, the V165A, A179P and KR186,7AA
mutants were exclusively present in the non chromatin-
bound S1 fraction (Fig. 3B, left panel, lanes 5 to 7). As
expected, the expressed YFP was only detected in the S1
fraction, whereas the Nup62 was detected in P1 fraction
(Fig. 3B, right panel). In order to confirm that the wild
Effects of different IN mutants on yeast growth Figure 2
Effects of different IN mutants on yeast growth. HP16 yeast cells were transformed with the wild type IN and different 
IN mutant expressors, as indicated. A. Expression of different IN mutants in HP16 yeast cells. Equal amounts of cells were 
grown in inducible media for 6 hr and cells were collected, lysed and subjected to IP with anti-HIV serum followed by WB with 
anti-IN antibody (upper panel). Additionally, 1/10 of the yeast cell lysate was analyzed by SDS-PAGE and the endogenous yeast 
β-actin was detected by anti-actin WB (lower panel). B. Each transformed yeast population was first grown in non-inducible 
selective media overnight. Then equal amounts of transformed yeast cells were grown either in non-inducible media (upper 
panel) or in the inducible media (lower panel) at 30°C for 24–36 hr. Yeast growth was monitored by measuring each yeast cell 
culture density, as previously described. Means and standard deviations from three independent experiments are shown. C. 
The growth of yeast in the absence of IN expression (left panel) or in the presence of IN expression (right panel) was also 
tested by the "drop test" on agar plate, as described.Retrovirology 2008, 5:102 http://www.retrovirology.com/content/5/1/102
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type IN and the D64E and K136A mutants were indeed
associated with the chromatin, the chromatin-bound P1
fractions were further treated with DNase and salt to
release the chromatin-bound proteins into the soluble
fraction (S2). After being treated with DNase and salt, all
of the chromatin-bound IN protein was released into S2
fraction (Fig. 3B, left panel; lanes 2 to 4). However, the
Nup62 protein remained in the insoluble fraction (P2)
(Fig. 3B, right panel). These results indicate that, similar to
that in yeast, the lethal phenotype-defective IN mutants
were impaired for their association with the cellular chro-
matin in mammalian cells.
To exclude the possibility that the loss of the ability to
bind chromatin by these lethal phenotype-defective IN
mutants is caused by a defect in nuclear translocation, we
The lethal phenotype-defective IN mutants lack chromatin binding ability Figure 3
The lethal phenotype-defective IN mutants lack chromatin binding ability. A. Chromatin binding ability of IN in 
yeast cells. After growing in IN-inducible media for 3h, different IN expressor-transformed yeast cells were lysed. Whole cell 
extracts were incubated with 50 or 200mM NaCl for 20 min before the separation of chromatin-bound and non-chromatin-
bound fractions. Both fractions were subjected to WB using anti-IN antibody (left panel).  Right panel: The INwt-expressing 
yeast cells were fractionated into chromatin- and non-chromatin-bound fractions and the presence of the Lys20/21 protein 
was detected by WB using anti-Lys20.21 antibody.  B. 293T cells transfected with different HA-tagged-IN expressors were 
lysed in cold CSK I buffer (0.5% Triton X-100), fractionated and the presence of HA-IN in the chromatin-bound and non-chro-
matin-bound fractions was analyzed by IP and WB with anti-HA antibodies (left panel). In parallel, the presence of the nuclear 
pore complex-associated protein Nup62 or YFP in different fractions of 293T cells or cells transfected with a SVCMV-YFP 
expressor was also analyzed by using anti-Nup62 and anti-GFP antibodies (right panel). S1: Supernatant (non-chromatin-bound 
fraction); P1: Pellet (chromatin-bound fraction); S2: DNase-released chromatin-associated proteins in P1; P2: insoluble, 
cytoskeletal, and nuclear matrix proteins in P1.Retrovirology 2008, 5:102 http://www.retrovirology.com/content/5/1/102
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analyzed intracellular localization of different IN mutants
by immunofluorescence in COS-7 cells. To avoid passive
diffusion of the relatively low molecular weight IN pro-
tein into the nucleus, we constructed YFP-IN fusion pro-
teins by fusing each IN mutant to YFP. An IN deletion
mutant, YFP-IN1–212, which was previously shown to be
unable to be localized in the nucleus [19], was used as a
negative control. In contrast to the cytoplasmic distribu-
tion of YFP-IN1–212 (Fig. 4a and 4b), the wild type and all
other mutant IN fusion proteins tested were predomi-
nantly localized in the nucleus (Fig 4c to 41). These results
clearly indicated that yeast lethal phenotype-defective
mutants retained the ability to translocate into the
nucleus.
Differential binding of IN mutants to Ini1 or LEDGF/p75
Ini1/hSNF5 is a component of the chromatin remodeling
SWI/SNF complex and was first identified as an interact-
ing partner for HIV-1 IN [13,14]. A previous study by
Parissi et al has shown that the inactivation of the SNF5
gene in yeast abolished the IN-induced lethal phenotype
[29]. In order to determine if the failure of the IN mutants
to induce the lethal phenotype may be due to their inabil-
ity to bind to Ini1, we analyzed the interaction between
the mutant IN and Ini1 using a cell-based co-IP assay.
After co-transfection with each IN-YFP expressor and
pCGN-HA-Ini1 expressor into 293T cells, the binding of
IN-YFP to HA-Ini1 was analyzed by an anti-GFP IP fol-
lowed by an anti-HA WB. Unlike YFP alone (Fig. 5A lane
2), IP of all IN-YFP fusion proteins, including the wild
type IN and the three lethal phenotype-defective mutants,
were able to co-precipitate similar amounts of Ini1 (Fig.
5A. lanes 3–6). This suggests that mutations introduced at
amino acids V165, A179 and KR186,7 did not affect their
ability to interact with Ini1. Also, the total amount of HA-
Ini1 in each sample was evaluated by a sequential IP with
an anti-HA antibody followed by an anti-HA western blot.
Similar levels of HA-Ini1 were expressed in each sample
(Fig. 5A, lower panel).
Another known cellular protein that interacts with IN,
LEDGF/p75, has been shown to be a tethering factor that
links IN to the chromatin during the early stage of the viral
replication [5,6,41]. To test whether IN mutants that have
impaired chromatin-binding ability also have altered
binding to LEDGF/p75, we tested the interaction between
IN and LEDGF/p75 by using the same co-IP assay in 293T
cells. The SVCMV-IN-YFP expressor and a SVCMV-T7-
LEDGF expressor were co-transfected into 293T cells. Cells
were lysed 48 hrs post-transfection and the interaction of
Intracellular localization of different IN mutants Figure 4
Intracellular localization of different IN mutants. COS-7 cells were transfected with different SVCMVin-YFP-IN fusion 
protein expressors as indicated. Cells were incubated with primary rabbit anti-GFP antibody followed by secondary FITC-con-
jugated anti-rabbit antibodies and the nuclei were stained with DAPI. Cells were visualized on a Carl Zeiss microscope (Axio-
vert 200) with a 63× oil immersion objective.Retrovirology 2008, 5:102 http://www.retrovirology.com/content/5/1/102
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IN-YFP and T7-LEDGF/p75 was analyzed by an anti-GFP
IP followed by an anti-T7 WB. Our results confirmed the
specific interaction between the IN and LEDGF/p75, since
only the wild type IN-YFP, not YFP alone, was able to co-
precipitate T7-LEDGF/p75 (Fig. 5B, compare lane 3 to
lane 2). Interestingly, all three IN mutants (V165A,
A179P, KR186,7AA) which lost their chromatin-binding
ability failed to interact with LEDGF/p75 (Fig. 5B, Lanes
4–6). To rule out the possibility that the differences in
binding for each mutant may be due to different expres-
sion levels of T7-LEDGF/p75 in the transfected cells, each
cell lysate was further evaluated with an IP using an anti-
T7 antibody followed by anti-T7 WB. Similar levels of T7-
LEDGF/p75 were expressed in each population of trans-
fected cells (Fig. 5B, lower panel). Together, these data
indicate that chromatin binding-impaired mutants are
unable to bind to LEDGF/p75.
HIV-1 encoding the lethal phenotype-defective IN 
mutations are replication defective and the defect can be 
partially complemented by the IN D64E mutant
In order to characterize the effect of these lethal pheno-
type-defective mutants on HIV replication, and whether
their impaired activity can be complemented by an IN
class 1 catalytic mutant, we introduced each of these IN
mutations into a previously described single-cycle HIV-1
replication system and evaluated viral replication [19,42].
Each IN mutant was first introduced into a CMV-Vpr-RT-
IN expressor and then co-transfected with the RT/IN-
deleted HIV provirus NL4.3lucΔBgl/ΔRI and a VSV-G
expressor into 293T cells to generate VSV-G-pseudotyped
HIV-1. In parallel, the VSV-G-pseudotyped wild type virus
(vINwt) and the IN class I mutant D64E virus (vD64E)
were also included as controls. After production of each
virus stock, the virion-incorporated RT, IN and Gag were
Characterization of IN mutants binding to Ini1 and LEDGF/p75 Figure 5
Characterization of IN mutants binding to Ini1 and LEDGF/p75. A. Interaction of the INwt and mutant with Ini1. Dif-
ferent IN-YFP plasmids, as indicated, were co-transfected with pCGN-HA-Ini1 in 293T cells.  At 48 hrs post-transfection, cells 
were lysed and immunoprecipitated with rabbit anti-GFP antibody and subjected to WB with anti-HA antibody to measure the 
amount of co-precipitated Ini1 (upper panel). The same membrane was stripped and blotted with anti-GFP antibody to detect 
IN-YFP and YFP expression (middle panel). The unbound Ini1 was also checked by sequential anti-HA IP followed by WB with 
the same antibody (lower panel). B. Lethal phenotype-defective IN mutants do not bind to LEDGF/p75.  Different IN-YFP 
expressors were co-transfected with T7-LEDGF expressor in 293T cells.  Cells were lysed 48 hrs post-transfection, whole-cell 
protein extracts were immunoprecipitated with rabbit anti-GFP followed by a WB using mouse anti-T7 HRP-conjugated anti-
body to detect the co-precipitated T7-LEDGF (upper panel). Also, the expressions of IN-YFPs were detected using an anti-
GFP HRP-conjugated antibody (middle panel). The unbound T7-LEDGF in the cell lysate was also checked by sequential IP with 
anti-T7 antibody followed by a WB with the same antibody (lower panel). Retrovirology 2008, 5:102 http://www.retrovirology.com/content/5/1/102
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analyzed by WB using an anti-HIV serum. Each IN mutant
virus contained similar levels of IN, RT, and Gag proteins,
compared to the wild type virus (Fig. 6A), indicating that
incorporation of RT and IN, as well as HIV-1 Gag process-
ing, was not affected by introducing various IN mutations.
To test the infectivity of the IN mutant viruses, we infected
the C8166 CD4+ T cell line with equal amounts of VSV-G-
pseudotyped IN mutant viruses (at 5 cpm of RT activity/
cell). Since all IN mutant viruses contained a luciferase
(luc) gene in place of the nef gene, viral infectivity was
monitored by using a sensitive luciferase assay, as
described previously [19]. The wild type IN virus infection
resulted in a high level of luc activity and peaked (1.5 ×
105 RLU) at 64 hrs post-infection in dividing C8166 cells
(Fig. 6B). The infection of the class I mutant D64E virus
Effects of lethal phenotype-defective IN mutants on VSV-G-pseudotyped HIV-1 replication Figure 6
Effects of lethal phenotype-defective IN mutants on VSV-G-pseudotyped HIV-1 infection. 293T cells were co-
transfected with the RT/IN/Env-deleted NL4.3Luc/DBg/DRI provirus, the VSV-G expressor and different Vpr-RT-IN 
expressors.  After 48 hrs of transfection, viral particles were harvested and concentrated by ultracentrifugation.  A. Equal 
amounts of viral particles were lysed and loaded on an SDS-PAGE and analyzed by anti-HIV WB.  B. To assess viral infection, 
equal amounts of virions were used to infect the CD4+ C8166 T cell line.  At different time points, equal cell numbers were 
collected and the HIV infection was evaluated by luciferase assay.  C. 12 hrs post-infection, 1x106 C8166 cells were lysed and 
the total viral DNA from each sample was analyzed by HIV specific PCR and visualized in 1% agarose gel. The positive control 
was loaded in lane 14.  D. To test the functional complementation of IN mutants, different combinations of Vpr-RT-IN mutant 
expressors, as indicated, were co-transfected with NL4.3Luc/DBg/DRI provirus and VSV-G expressor in 293T cells.  After 48 
hrs of transfection, viral particles were collected, and used to infect dividing C8166 cells. At 72 hrs post-infection and the cell-
associated luciferase activity was measured. NC: negative control. The results are representative of three independent experi-
ments.Retrovirology 2008, 5:102 http://www.retrovirology.com/content/5/1/102
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resulted only in a basal level of luc activity that was
approximately 104-fold lower than the wild type (Fig. 6B).
Interestingly, when C8166 cells were infected with VSV-G-
pseudotyped viruses containing the chromatin binding-
defective IN mutants, the levels of luc activity were similar
to the D64E mutant virus throughout the 6-day period
(Fig. 6B). These results indicate that, like the class I D64E
mutant virus, the chromatin binding-deficient V165A,
A179P and KR186,7AA mutant viruses were replication
defective in C8166 cells.
To determine whether the replication defect in IN mutant
viruses could be due to a defect at the reverse transcription
level, we analyzed viral DNA synthesis following infection
of C8166 cells with each IN mutant. The levels of late
reverse transcription products were analyzed by semi-
quantitative PCR 12 hrs post-infection with HIV-1-spe-
cific 5'-LTR-U3/3'-Gag primers [19]. Total viral DNA syn-
thesis during infections with the V165A-, A179P- and
KR186,7AA-containing viruses was similar to that follow-
ing infection with the wild type and D64E mutant viruses
(Fig. 6C). We also performed a wild type HIV infection in
the presence of AZT (10 μM) to rule out the possibility of
proviral plasmid carry over during viral production, and
the data showed that no viral DNA was detected (data not
shown). These results indicate that all three lethal pheno-
type-defective IN mutants did not significantly affect
reverse transcription during single-cycle replication of
HIV-1.
Since the V165A, A179P and KR186,7AA IN mutants, but
not class I mutant D64E, failed to both induce yeast
lethality and associate with chromatin, it is tempting to
postulate that the lethal phenotype-defective mutations
affect a different step in the HIV-1 replication than the
D64E mutant. If true, the complementation with the
D64E mutant may restore the infecting ability of these
lethal phenotype-defective IN mutants. In fact, several
previous studies have reported that the defect of some IN
mutants can be functionally complemented by the incor-
poration of a Vpr-IN fusion protein into the virion during
virus production [33,43,44]. To test this possibility, we
co-transfected 293T cells with the HIV-1 provirus
NL4.3lucΔBgl/ΔRI, the VSV-G expressor and a mixture of
different Vpr-RT-IN mutants, as indicated in Fig. 6D. VSV-
G-pseudotyped virions were collected 48 hrs post-trans-
fection and equal amounts of each jvirus (5 cpm of RT
activity per cell) were used to infect C8166 cells. As
expected, while infection with the wild type virus yielded
a high luc level (8.5 × 106 RLU/20 μl) (Fig. 6D, left panel),
the D64E and V165A mutant viruses only induced a basal
level of luc activity (Fig. 6D, right panel). Interestingly,
when C8166 cells were infected with viruses containing
two different IN mutant proteins, such as D64E/V165A,
D64E/A179P, or D64E/KR186,7AA, the luc values were
much higher than infection with D64E or V165A virus
(Fig. 6D, right panel). These results were further sup-
ported by the observation that there was no complemen-
tation between V165A and KR186,7AA mutants when
they were co-incorporated in the virus (Fig. 6D, right
panel). Of note, the complementation level of D64E for
A179P and KR186,7AA mutants was lower than that of
V165A mutant. These differences may be due to the fact
that the non-conservative substitutions in A179P or
KR186,7AA mutants profoundly affect the functions of
IN, including its catalytic activity. Nevertheless, the data
presented here indicate that the lethal phenotype-defec-
tive mutations and the D64E substitution affect different
steps during the viral replication.
Discussion
HIV-1 IN plays a critical role in several steps of the early
viral replication, including reverse transcription, nuclear
import of viral DNA and integration [18-23]. In order to
further investigate different functions of HIV-1 IN and the
molecular mechanisms involved, numbers of in vitro and
in vivo assays, including a yeast IN expression system, have
been developed to specifically assess the different activi-
ties of HIV-1 IN. Caumont et al initially reported that the
expression of HIV-1 IN in some yeast strains resulted in a
lethal phenotype [26]. Several studies have suggested that
the IN-induced lethal phenotype may be related to the cat-
alytic activity of IN, as an IN catalytic mutant (D116A)
was unable to induce lethality in yeast [27,28]. However,
another study recently reported that a mutation targeting
the amino acid E152, another of the three residues essen-
tial for the catalytic activity of IN, had no effect on the
lethality in yeast cells [30]. Thus, the mechanism for the
IN-induced lethal phenotype in yeast still remains to be
fully understood. In this study, we introduced different IN
mutants into the HP16 strain of S. cerevisiae and tested
their effects on yeast viability. Three IN mutants (V165A,
A179P and KR186,7AA) were identified as lethal pheno-
type-defective mutants in HP16 cells (Fig. 2). In contrast
to a previous study [27], our experiments revealed that
this IN-induced lethality was independent of the catalytic
activity of IN, since two catalytically inactive IN mutants
(D64E and D116A) were still able to induce the lethal
phenotype in our experimental system. While one expla-
nation for this discrepancy could be the different yeast
strains used in different laboratories, our results suggest
that another function of HIV-1 IN, rather than its catalytic
activity, may contribute to its lethal activity in HP16 yeast
cells.
A recent study has demonstrated that the expression of IN
in yeast could mediate the integration of DNA containing
viral LTRs into the yeast genome [36]. Thus, it appears that
the molecular mechanisms underlying the activity of IN in
both yeast and mammalian cells are similar. Given thatRetrovirology 2008, 5:102 http://www.retrovirology.com/content/5/1/102
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chromatin targeting by IN is a prerequisite step for viral
DNA integration [5-7,41], we investigated whether the
yeast lethal phenotype-defective mutants would also have
a defect in chromatin binding. Interestingly, the chroma-
tin binding experiments showed that three lethal pheno-
type-defective mutants were impaired for binding to
chromatin in both yeast and mammalian cells. The
reduced chromatin binding ability of the IN mutants did
not appear to result from the diminished nuclear entry of
IN as we found that the nuclear translocation of these IN
mutants was intact. Overall, these data clearly indicate
that these mutations at the C-terminal region of the cata-
lytic core domain of IN severely affected its ability to inter-
act with host cell chromatin.
We further investigated the possible mechanism underly-
ing this loss of chromosomal binding by testing the inter-
actions of these IN mutants with two known IN-
interacting cellular proteins. The first, Ini1, is a homolog
to the yeast SNF5 protein and was found to bind to HIV-
1 IN in a yeast two-hybrid system and was shown to
increase the efficiency of integration in an in vitro assay
[13]. Also, inactivation of the SNF5 gene has been shown
to abolish the IN-induced lethal phenotype in yeast [29].
However, our results indicate that three yeast lethal phe-
notype-defective mutants were able to bind to Ini1 at a
level comparable to the wild type IN, (Fig. 5A), indicating
that the loss of lethality in these IN mutants is not related
to their Ini1-binding ability. However, at this point, we
still cannot rule out the possibility that SNF5 may act on
other unidentified steps to affect the IN-induced lethal
phenotype.
The second cellular protein examined, LEDGF/p75, has
been previously shown to directly interact with HIV-1 IN
[4]. LEDGF/p75 functions in the tethering of IN to the
host chromosome, a step essential for HIV-1 integration
and viral replication [5,6,41]. Interestingly, we found that
all three lethal phenotype-defective IN mutants did not
interact with LEDGF/p75 (Fig. 5B) in 293T cells. Previous
studies have identified two regions within IN that are
involved in the interaction with LEDGF/p75: the region
around W131 and W132 and the region from I161 to
E170 [10]. In line with this observation, the structural
analysis of IN suggests that α1 and α3 helices in the B
chain of IN, in addition to the α4/α5 connector (residues
166–171) and α5 helix in the A chain form the founda-
tion of the LEDGF/p75 binding site [8,9]. It has also been
shown that the V165A and L172A/K173A mutants were
unable to bind LEDGF/p75 in vitro [9]. In this study, we
confirmed that the V165A mutant was indeed unable to
interact with LEDGF/p75. Moreover, two other IN
mutants (A179P and KR186,7AA) were identified in this
study that were incapable of binding to both LEDGF/p75
and to chromatin. As both mutations are located in the
region encompassing amino acids from 171 to 186, which
has been predicted to form the putative helix-α5 structure
and/or the α5/α6 connector (residues 166–171) [45], it
suggests that these regions and/or the helical structure
play an important role in the interaction between IN and
LEDGF/p75 and its chromatin tethering function. How-
ever, an important question that needs to be addressed is
how this region contributes to the interaction between IN
and LEDGF/p75. Interestingly, a recent study by Berthoux
et al demonstrated that the lysine at position 186 is critical
for IN multimerization. However, their study also indi-
cated that the K186Q mutant interacted with LEDGF/p75
as efficiently as the wild type IN in a two-hybrid assay
[35]. In contrast, another recent report by Mckee et al con-
firmed that mutations introduced in the KRK(186–188)
region affected IN multimerization. Furthermore, their
study also showed that this KRK(186–188) region is
important for IN binding to LEDGF/p75 [46]. Since our
results also showed the inability of the KR186,7AA
mutant to bind to LEDGF/p75 and host chromatin, a log-
ical next question is whether our other lethal phenotype-
deficient mutants in this region could also affect protein
multimerization. Currently, experiments are under way to
address this question. Interestingly, it has been reported
that there is no yeast homolog of LEDGF/p75 [36]. There-
fore it is tempting to speculate that there may be other
host protein(s) in yeast that contribute to chromatin-tar-
geting of IN. In this regard, there is another cellular pro-
tein, HSP60, has also been shown to be important in IN-
induced lethality in yeast [47]. However, the role that
HSP60 plays in the chromatin targeting and/or other
activities of IN in yeast still awaits further characteriza-
tion.
The effect of these yeast lethal phenotype-defective
mutants on HIV-1 replication was also evaluated using a
previously described single cycle infection system with
VSV-G-pseudotyped HIV. Similar to the IN class I mutant
D64E, all yeast lethal phenotype-defective IN mutant
viruses were replication deficient. Using semi-quantitative
PCR, we showed that all three yeast lethal-defective IN
mutants did not affect reverse transcription and these IN
mutant viruses could be complemented by the D64E
mutant (Fig. 6D). These results are consistent with a pre-
vious report by Lu et al that showed that the catalytically
active IN mutants V165A and K186Q were able to com-
plement the D64N/D116N mutant virus [33]. It should
be noticed that D64E was less efficient in complementing
the A179P and KR186,7AA mutants than the V165A
mutant (Fig. 3C). It is possible that introduction of a pro-
line at residue 179, or the non-conservative amino acid
substitutions for KR186,7, had a more profound impact
on the activities of IN, including its catalytic function.Retrovirology 2008, 5:102 http://www.retrovirology.com/content/5/1/102
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Overall, this study has established a functional correlation
between the IN-induced lethality in yeast and the inability
of IN to associate with host chromatin and bind to
LEDGF/p75. This suggests that this yeast-based IN expres-
sion system may be a valuable system for studying the
molecular mechanisms underlying the chromatin binding
activity of HIV-1 IN, as well as for the high-throughput
screening anti-IN molecules that specifically prevent IN
from associating with chromatin. Also, our study suggests
that a region encompassing amino acids 171 to 186,
which was previously predicted to form the alpha-helix-5
structure [45], may play an important role in the binding
of IN to both chromatin and LEDGF/p75. A more detailed
analysis will be required to fully elucidate how this region
and/or the secondary structure of IN contribute to this
particular function of IN during viral replication.
Materials and methods
Yeast strains, culture media, and growth conditions
The protease-deficient S. cerevisiae HP16 strain (MATa
ura3-52; his3Δ1; leu2; trp1Δ63; prb1-1122; pep4-3 prc1-407)
has been previously described Plasmid transformation
was performed using the lithium acetate method The fol-
lowing culture media were used: 1) yeast complete
medium YPD (1% yeast extract, 2% bactopeptone, 2%
glucose) and 2) yeast liquid selective media: YNB lacking
tryptophan (0.67% yeast nitrogen base without amino
acids, 2% galactose or raffinose). Amino acids and bases
(20–30 mg/1) were added as required. Solid selective
media were obtained by supplementing liquid media
with 2% bacto-agar. Yeast cells were grown at 30°C.
Cell lines and transfections
Human embryonic kidney 293T and the African green
monkey kidney COS-7 cell lines were cultured in Dul-
becco's Modified Eagles Medium (DMEM) supplemented
with 10% fetal calf serum (FCS) and 1% penicillin and
streptomycin. Human CD4+ C8166 T cell line was main-
tained in RPMI-1640 medium supplemented with 10%
FCS and 1% penicillin and streptomycin. 293T cells and
COS-7 cells were transfected with the standard calcium
phosphate precipitation technique, as described previ-
ously [48].
Plasmids, antibodies and chemicals
To test the ability of the wild type HIV-1 IN to induce the
lethal phenotype in the HP16 yeast strain, one HIV-1 IN
yeast expression plasmid (p424Gal1-IN) was constructed
by inserting a PCR-generated BamHI-PstI fragment con-
taining the IN sequence into the high copy yeast expres-
sion plasmid p424Gal1 This plasmid contains a galactose-
inducible Gal1 promoter and a tryptophan (Trp) selection
marker. The different plasmids expressing mutant IN were
generated using a two-step mutagenic PCR-based method
[49] with primers containing the desired mutations. The
amplified IN cDNA containing the specific mutations was
then cloned into the p424Gal1 vector. All IN mutants
were sequenced to confirm the presence of mutations.
The RT/IN/Env gene-deleted provirus (NL4.3Luc/ΔBg/
ΔRI) has been previously described [19]. To complement
RT/IN and Env defects of NL4.3Luc/ΔBg/ΔRI, a vesicular
stomatitis virus G glycoprotein (VSV-G) expressor and a
SVCMV-Vpr-RT-IN fusion protein expressor [50] were
used in this study. To test the effects of different IN
mutants on viral infection, cDNAs encoding the IN
mutants, including V165A, A179P, KR186,7AA or D64E,
were introduced into the SVCMV-Vpr-RT-IN expressor by
PCR-based method as described before [19]. To test the
association between HIV-1 IN and cellular chromatin, dif-
ferent hemagglutinin (HA)-tagged IN expression plasmids
(SVCMV-HA-IN) were constructed by fusing the IN cDNA
to the 3' end of cDNA encoding the HA sequence
(MASYPYDVPDYASL). For the intracellular localization
experiments and co-IP assay, SVCMV-IN-YFP and SVCMV-
YFP-IN were constructed by using the same strategy
described previously [19,42]. To construct SVCMVin-T7-
LEDGF, the LEDGF cDNA derived from a pFT-1-LEDGF
plasmid [51] was cloned into a SVCMVin vector [42]. The
pFT-1-LEDGF plasmid was kindly provided by Dr. A.
Engelman through the AIDS Research Reference Reagent
Program, Division of AIDS, NIAID, NIH. The Ini1
expressor pCGN-HA-Ini1 used in this study was described
previously [15].
Antibodies used in the immunofluorescence assay, IP or
WB were as following: the HIV-1 positive human serum
162 was previously described [52]. The mouse mono-
clonal antibody against yeast β-actin (ab8224) was pur-
chased from Abcam. The rabbit anti-GFP and mouse anti-
HA antibodies were purchased from Molecular Probes,
and the monoclonal anti-Nup62/p62 antibody was pur-
chased from Sigma. Anti-IN antibodies were kindly pro-
vided by Dr. Grandgenett through the AIDS Research
Reference Reagent Program, Division of AIDS, NIAID,
NIH.
Evaluation of the lethal phenotype induced by HIV-1 IN in 
the HP16 yeast strain
The experimental procedures to evaluate protein expres-
sion and yeast growth arrest activity were described previ-
ously [48]. Briefly, HP16 cells transformed with p424Gal1
or p424Gal1-IN wild type or mutant plasmids were first
grown in an IN non-inducible selective medium (Trp-, 2%
raffinose (raf+)) for 2 days. Then, equal amounts of trans-
formed HP16 yeast cells were inoculated into IN-non-
inducible (Trp-, 2% raf+) or IN-inducible (Trp-, 2% galac-
tose (gal+)) media for the liquid assay. After cultivation
while shaking at 30°C for 24–36 h, yeast growth was
monitored by measuring the culture density spectropho-Retrovirology 2008, 5:102 http://www.retrovirology.com/content/5/1/102
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tometrically at 600 nm. Meanwhile, equal amounts of
transformed yeast cells were serially diluted and spotted
onto either IN non-inducible or inducible agar plates for
the "drop test". After incubation for 3 to 5 days, yeast
growth was recorded photographically. To detect IN
expression in yeast, equal amounts of transformed yeast
cells were grown in IN-inducible media for 6 hr, then cells
were pelleted by centrifugation and lysed in RIPA buffer
by vortexing with glass beads for 1 min on ice, four times.
Supernatants were collected and IN was immunoprecipi-
tated with anti-HIV antibodies. Immunoprecipitates were
then resolved by 12.5% SDS-PAGE followed by WB using
rabbit anti-IN antibody.
Yeast chromatin-binding assay
HP16 cells harboring either p424-Gal1-IN wild type or
p424-Gal1-IN encoding the V165P, A179P or KR186,7AA
mutants were grown at 30°C in IN-non-inducible (Trp-,
2% raf+) media to a cell density of 0.25 A600. Cells were
then induced with IN-inducible (Trp-, 2% gal+) media for
3 h. Cells were spheroplasted and fractionated, as
described previously [37] with minor modifications.
Briefly, cells were resuspended in spheroplasting buffer
(1% yeast extract, 2% peptone, 0.2% galactose, 50 mM
KH2PO4/K2HPO4 (pH 7.5), 0.6 M Sorbitol, 10 mM DTT)
containing 20 μl of 10 mg/ml of Zymolyase 100T. Sphe-
roplasts were centrifuged for 3 min at 1000 × g and then
resuspended in 200 μl of ice-cold lysis buffer (0.1 M
Pipes-KOH, 10 mM DTT, pH 9.4) containing protease
inhibitors and lysed in 1% Triton X-100, yielding whole
cell extracts. Chromatin and non-chromatin fractions
were separated by centrifugation for 15 min at 15 000 × g
and subjected to WB analysis.
Chromatin binding assay in 293T cells
The association of HIV-1 IN with chromatin in mamma-
lian cells was analyzed using a previously described chro-
matin binding assay [39]. Briefly, 293T cells were
transfected with different SVCMV-HA-IN mutants. At 36–
40 hrs post-transfection, cells were lysed for 15 min on ice
with cold CSK I buffer (10 mM Pipes pH 6.8, 100 mM
NaCl, 1 mM EDTA, 300 mM sucrose, 1 mM MgCl2, 1 mM
DTT) supplemented with 0.5% (v/v) Triton X-100 and
protease inhibitors. Cell lysates were centrifuged at 500 ×
g, for 3 min at 4°C to separate Triton-soluble (S1) and
non-soluble (P1) fractions. Half of the S1 fraction was fur-
ther lysed in RIPA buffer (150 mM Tris-HCl, pH 8.0, 150
mM NaCl, 0.5% DOC, 0.1% (w/v) SDS, 1% (v/v) NP-40).
The P1 fraction, which contains chromatin-bound,
nuclear matrix-bound and insoluble proteins, was divided
into two equal portions. One half was resuspended in
RIPA buffer (the P1 fraction). The remaining half was
resuspended in CSK II buffer (10 mM Pipes pH 6.8, 50
mM NaCl, 300 mM sucrose, 6 mM MgCl2, 1 mM DTT)
and treated with DNase (10 unit) for 30 min. It was then
extracted with 250 mM (NH4)2SO4 for 10 min at 25°C
and centrifuged at 1200 × g for 6 min at 4°C. The super-
natant (S2 fraction, containing DNase-released chroma-
tin-associated proteins) and pellet (P2, containing
insoluble, cytoskeletal, and nuclear matrix proteins) were
collected and resuspended in RIPA buffer. All fractions
were immunoprecipitated with anti-HA antibodies fol-
lowed by a WB with the same antibody.
Immunofluorescence assay
COS-7 cells were grown on glass cover slips (12 mm2) in
24-well plates for 24 hr and then transfected with different
IN expression plasmids (CMV-YFP-IN). After 48 hr, cells
on the cover slip were fixed and permeabilized for 30 min
in methanol/acetone (1:1 ratio) at room temperature. The
glass cover slips were incubated with a primary rabbit
anti-GFP antibody followed by a secondary FITC-conju-
gated anti-rabbit antibody. Nuclei were stained with
DAPI. Cells were visualized on a Carl Zeiss microscope
(Axiovert 200) with a 63× oil immersion objective.
Co-immunoprecipitation assay
The interaction between IN and the cellular proteins Ini1
or LEDGF/p75 was verified by co-immunoprecipitation.
293T cells were first cotransfected with SVCMV-IN-YFP
and pCGN-HA-Ini1 or SVCMVin-T7-LEDGF. Forty-eight
hrs post-transfection, cells were lysed with 0.25% NP-40
(RPMI-1640 medium containing 0.25%NP-40) and a
protease inhibitor cocktail (Roche) on ice for 30 min and
the extracts clarified by centrifugation at 14,000 rpm for
30 min. To test the interaction between IN and Ini1, IN-
bound Ini1 was detected by immunoprecipitation with
anti-GFP followed by a WB using an anti-HA antibody. To
detect the IN/LEDGF complex, the extracts were subjected
to immunoprecipitation with rabbit anti-GFP antibody
and followed by a WB using a mouse anti-T7 antibody.
Meanwhile, the unbound HA-Ini1 and T7-LEDGF pro-
teins in the remaining cell lysates were checked by an
immunprecipitation with anti-HA or anti-T7 antibodies
followed by a WB with the same antibody. The expression
of IN-YFP was checked by a WB with mouse anti-GFP anti-
body.
Single cycle viral replication and infection
Production of different single-cycle replicating viral stocks
and the measurement of the viral titer were previously
described [50]. Briefly, 293T cells were co-transfected with
NLlucΔBglΔRI provirus, a VSV-G expressor and different
wild type or mutant IN expressors (CMV-Vpr-RT-IN).
Supernatants were collected 48 hr post-infection and
ultracentrifuged with Ti71 rotor (Beckman) at 40,000 rpm
to purify virions. Viral titers were quantified by RT activity
assay [53]. To analyze the composition of the virions,
equal amount of the viral stocks were lysed and proteinsRetrovirology 2008, 5:102 http://www.retrovirology.com/content/5/1/102
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were separated by SDS-PAGE on a 12.5% gel, followed by
a WB with anti-HIV serum.
To test the effect of the IN mutants on viral infection,
dividing C8166 cells were infected with equivalent VSV-
G-pseudotyped, single cycle replicating viruses (5 cpm/
cell) for 4 hr. Infected cells were washed and cultured in
fresh RPMI-1640 media. At different time points post-
infection, 1 × 106 cells from each sample were collected,
washed twice with PBS, lysed with 50 μl of luciferase lysis
buffer (Fisher Scientific). Either 10 or 20 μl of the cell
lysates were analyzed by the luciferase assay and meas-
ured by using a Top-Count®NXT™ Microplate Scintillation
and Luminescence Counter (Packard, Meriden), Luci-
ferase activity is reported as relative luciferase units (RLU).
Measurement of reverse transcription by PCR
C8166 cells were infected with equal amounts of the VSV-
G-pseudotyped IN wild type or mutant viruses for 2 hrs.
Twelve hrs post-infection, 1 × 106 cells were collected and
processed to detect the total viral DNA synthesis, as
described previously [19]. Briefly, 1 × 106 cells were col-
lected, washed twice with PCR washing buffer (20 mM
Tris-HCl, pH8.0, 100 mM KCl) and lysed in lysis buffer
(PCR washing buffer containing 0.05% NP-40, 0.05%
Tween-20). Lysates were then incubated at 56°C for 30
min with proteinase K (100 μg/ml) and at 90°C for 10
min. DNA was isolated by phenol-chloroform extraction.
All lysates were serially diluted 2-fold and subjected to
PCR analysis using the HotStar Taq Master Mix kit (QIA-
GEN, Mississauga, Ontario). The primers used to detect
late reverse transcription products were: 5'-LTR-U3, 5'-
GGATGGTGCTTCAAGCTAGTACC-3' (nt position 8807,
+1 = start of BRU of transcription initiation); 3'-Gag 5'-
ACTGACGCTCTCGCACCCATCTCTCTC-3' (nt position
329). PCR products were visualized in 1% agarose gel.
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